Dentsply Sirona
XRAY
$12.12
-7.97%
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies, offering a comprehensive portfolio that includes dental consumables, lab products, CAD/CAM and imaging technology, and specialty products in orthodontics, endodontics, and implantation. The company holds a leading market position as a result of the 2016 merger between Dentsply International and Sirona Dental Systems, with a broad distribution network that reaches dental practices and labs globally. Currently, the stock is under scrutiny as the company navigates a challenging turnaround, marked by recent quarterly losses and a strategic focus on innovation and cost management. Investors are debating the sustainability of its recovery, given the mixed financial performance and the potential for margin improvement in a competitive dental market.…
XRAY
Dentsply Sirona
$12.12
Investment Opinion: Should I buy XRAY Today?
Rating: Hold. The stock is a speculative turnaround play with deep value characteristics, but the lack of fundamental improvement warrants caution. The analyst consensus is 'hold' with an average target of $13.44, implying modest downside from the current price of $14.13. The thesis is that the stock is cheap on sales (0.62x PS) and forward earnings (9.12x PE), but the turnaround is unproven, and the risk of continued losses is high.
Sign up to view all
XRAY 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The stock is cheap on a sales basis, but the lack of revenue growth and profitability are major concerns. The recent price surge could be a short-term rally in a longer-term downtrend. To upgrade to bullish, we would need to see evidence of sustainable revenue growth and margin expansion. To downgrade to bearish, we would need to see further deterioration in fundamentals or a breakdown below the 52-week low.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Dentsply Sirona's 12-month outlook, with a consensus price target around $13.72 and implied upside of +13.2% versus the current price.
Average Target
$13.72
0 analysts
Implied Upside
+13.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$9 - $17
Analyst target range
The target price range is wide, from $9.00 to $17.00, reflecting high uncertainty about the company's future. The high target assumes that the company can successfully execute its turnaround, improve margins, and return to growth, while the low target prices in continued revenue declines and margin compression. Recent institutional ratings show a mix of actions, with Barclays maintaining an Underweight, UBS reiterating a Buy, and B of A upgrading from Neutral to Buy in February 2026. This mixed sentiment suggests that while some see value, others remain skeptical about the company's ability to overcome its challenges. The wide spread in targets indicates that the market is not confident in a single outcome, which could lead to continued volatility.
Bulls vs Bears: XRAY Investment Factors
XRAY presents a classic value-versus-value-trap debate. On the bull side, the stock trades at a deep discount to peers (0.62x PS vs. 2.5x industry), has strong recent momentum, and has attracted some analyst upgrades. On the bear side, revenue is stagnant, margins are thin, and the company carries significant debt. The most critical tension is whether the recent price surge reflects a genuine fundamental improvement or merely a short-term bounce in a prolonged downtrend. Currently, the bear case has stronger evidence given the lack of top-line growth and profitability, but the valuation discount provides a margin of safety if the turnaround gains traction. The stock's fate hinges on the company's ability to stabilize revenue and expand margins in the coming quarters.
Bullish
- Deep Value at 0.62x Sales: XRAY trades at a price-to-sales ratio of 0.62x, a fraction of the industry average of 2.5x. This implies the market is pricing in significant distress, but if the turnaround gains traction, the stock has substantial re-rating potential.
- Positive Relative Strength Momentum: The stock has surged 21.3% over the past month and 24.3% over three months, outperforming the S&P 500 by 19.6 and 19.6 percentage points respectively. This momentum suggests improving investor sentiment and possible early signs of a recovery.
- Analyst Upside to Average Target: The average analyst target price is $13.44, implying about 5% downside from the current price of $14.13, but the high target of $17.00 suggests 20% upside if the turnaround exceeds expectations. With 16 analysts covering, the range reflects high uncertainty but also potential.
- Stable Consumables Segment: Consumables revenue of $430 million in Q1 2026 provides a recurring, less cyclical revenue stream. This segment helps stabilize the top line and supports the company's ability to generate cash flow during the turnaround.
Bearish
- Persistent Revenue Stagnation: Q1 2026 revenue of $880 million was essentially flat year-over-year (0.11% growth), and the company has seen sequential declines from $961 million in Q4 2025. This lack of top-line growth limits the potential for earnings recovery.
- Negative Earnings and Thin Margins: The company reported a net loss of $10 million in Q1 2026, with a net margin of -1.1%. Operating margin was just 3.4%, down from 7.2% a year ago, indicating that profitability is under pressure and the turnaround is far from complete.
- High Debt and Leverage: Debt-to-equity ratio stands at 1.84x, and the company's negative ROE of -44.6% highlights the burden of debt on shareholder returns. High leverage increases financial risk, especially if interest rates remain elevated.
- Wide Analyst Target Range: Analyst targets range from $9.00 to $17.00, a spread of nearly 90% from the low to high. This wide dispersion reflects deep uncertainty about the company's future, making the stock highly speculative and prone to volatility.
XRAY Technical Analysis
XRAY has exhibited a volatile, range-bound pattern over the past year, with the current price of $14.13 sitting near the upper end of its 52-week range (low of $9.41, high of $14.86). The 1-year price change is -1.19%, indicating that the stock has essentially flatlined over the long term, but the recent surge from the lows suggests a potential recovery. The stock is currently trading at 95% of its 52-week range, which typically signals strong momentum but also raises the risk of overextension.
Beta
0.87
0.87x market volatility
Max Drawdown
-42.8%
Largest decline past year
52-Week Range
$9-$15
Price range past year
Annual Return
-8.4%
Cumulative gain past year
| Period | XRAY Return | S&P 500 |
|---|---|---|
| 1m | +2.9% | +2.4% |
| 3m | +10.2% | +4.6% |
| 6m | -11.9% | +11.7% |
| 1y | -8.4% | +21.4% |
| ytd | +7.5% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
XRAY Fundamental Analysis
Revenue in the most recent quarter (Q1 2026) was $880 million, essentially flat year-over-year with a growth rate of 0.11%. This follows a trend of stagnant to declining revenue over the past several quarters, with Q4 2025 revenue of $961 million and Q3 2025 revenue of $904 million, indicating a lack of top-line momentum. The company's revenue segments show a split between Technologies and Equipment ($548 million) and Consumables ($430 million), with the latter being a more stable, recurring revenue stream. The flat growth suggests that the company is struggling to expand its market share in a mature industry, which is a key concern for investors.
Quarterly Revenue
$880000000.0B
2026-03
Revenue YoY Growth
+0.1%
YoY Comparison
Gross Margin
48.5%
Latest Quarter
Free Cash Flow
$104000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is XRAY Overvalued?
Given that XRAY's trailing twelve-month net income is negative (EPS of -$0.26), the price-to-earnings ratio is not meaningful, so I have selected the price-to-sales (PS) ratio as the primary valuation metric. The current PS ratio is 0.62x, which is significantly lower than the industry average of approximately 2.5x, indicating that the stock is trading at a substantial discount to its peers. This discount is likely justified by the company's poor profitability and stagnant growth, but it may also present a value opportunity if the turnaround succeeds. The forward PE ratio of 9.12x suggests that the market expects earnings to recover, but this is based on analyst estimates that may be optimistic.
PE
-3.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 24x~38x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-96.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated. The company's negative net income (EPS of -$0.26 TTM) and thin operating margin of 3.4% in Q1 2026 indicate that profitability is fragile. With a debt-to-equity ratio of 1.84x, the company is highly leveraged, and interest expenses of $24 million in Q1 2026 consume a significant portion of operating income. Revenue has been stagnant, with Q1 2026 growth of just 0.11% year-over-year, and the company has failed to generate consistent free cash flow, with TTM FCF of only $104 million. This combination of high debt, low margins, and stagnant sales makes the company vulnerable to any operational misstep or economic downturn.
FAQ
The key risks are: 1) Financial risk: high debt-to-equity of 1.84x and negative ROE of -44.6% could lead to financial distress if the turnaround fails. 2) Operational risk: revenue growth is flat at 0.11% YoY, and margins are thin (operating margin 3.4%), leaving little room for error. 3) Competitive risk: the dental industry is competitive, and the company may lose market share to more innovative rivals. 4) Macro risk: with a beta of 0.87, the stock is less volatile than the market, but a recession could hurt dental spending. The most severe risk is a continued decline in revenue, which could push the stock toward the 52-week low of $9.41, a 33% downside from the current price.
The 12-month forecast is uncertain, with a base case probability of 50% for a target range of $12-$14, a bull case probability of 25% for $15-$17, and a bear case probability of 25% for $9-$11. The base case assumes flat revenue and stable margins, while the bull case requires successful execution of the turnaround. The bear case would occur if the turnaround fails and revenue declines further. The most likely scenario is the base case, with the stock trading around the analyst average target of $13.44, but the wide range reflects high uncertainty.
XRAY appears undervalued on a price-to-sales basis, with a PS ratio of 0.62x versus the industry average of 2.5x. The forward PE of 9.12x also suggests the market expects earnings to recover. However, the trailing PE is negative due to losses, and the low valuation is justified by the company's poor profitability and stagnant growth. The market is pricing in a high probability of failure, but if the turnaround succeeds, the stock could re-rate significantly. The valuation implies that the market expects continued challenges, but the discount provides a margin of safety.
XRAY is a speculative buy at best. The stock trades at a deep discount to peers (0.62x PS vs. 2.5x industry), and the average analyst target of $13.44 is only 5% below the current price, but the high target of $17.00 suggests 20% upside. However, the company is unprofitable, with a negative EPS of -$0.26 TTM, and revenue growth is flat. The stock is suitable for investors who believe the turnaround will succeed and can tolerate significant volatility. For conservative investors, it is better to wait for evidence of sustained improvement in margins and revenue growth.
XRAY is more suitable for long-term investors with a high risk tolerance, as the turnaround story will take time to play out. The stock has a beta of 0.87, indicating lower volatility than the market, but the recent 21% one-month gain suggests short-term trading opportunities. However, the company's negative earnings and stagnant growth make it a risky short-term trade. For long-term investors, a minimum holding period of 3-5 years is recommended to allow the turnaround to materialize. The stock offers no meaningful dividend (yield 5.6% but payout ratio negative), so returns will depend on capital appreciation.